Product Information
PYRIDOSTIGMINE ER 180 MG TAB is a generic product labeled by Rising Pharma Holdings Inc., priced at $3.9963 per EA under NDC 64980022003. Its NADAC has been published 371 times since Aug 28, 2019.
FDA first approved this application on Aug 15, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
180 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
64980022003
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PYRIDOSTIGMINE BROMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA205464FDA Approved
8/15/2017
TE Code
AB
On Market Since
8/15/2017
Pharmacological Classes
Price Statistics
The NADAC for PYRIDOSTIGMINE ER 180 MG TAB has been published 371 times since Aug 28, 2019, and over the history we have for it it has declined 47.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.9963 per EA |
|---|---|
| All-time high | $7.6645 (Sep 11, 2019) |
| All-time low | $1.6459 (May 22, 2024) |
| 52-week high | $5.1534 |
| 52-week low | $3.9061 |
| Median price | $5.1105 |
| Average price | $5.0758 |
| Largest weekly change | +97.2% (Aug 21, 2024) |
| Weeks tracked | 371 |
| Tracking since | Aug 28, 2019 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Pyridostigmine Bromide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinesterase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PYRIDOSTIGMINE ER 180 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for PYRIDOSTIGMINE ER 180 MG TAB, manufactured by Rising Pharma Holdings Inc., is $3.9963 per EA (NDC 64980022003), effective Sep 30, 2026.
How has the price of PYRIDOSTIGMINE ER 180 MG TAB changed over time?
Over the history we have for it, the NADAC for PYRIDOSTIGMINE ER 180 MG TAB has declined 47.9%. It has been tracked across 371 weekly CMS publications since Aug 28, 2019.
What are the highest and lowest recorded NADAC prices for PYRIDOSTIGMINE ER 180 MG TAB?
Since Aug 28, 2019, the NADAC for PYRIDOSTIGMINE ER 180 MG TAB has ranged from a low of $1.6459 (May 22, 2024) to a high of $7.6645 (Sep 11, 2019), with a median of $5.1105 per EA.
Are there cheaper alternatives to PYRIDOSTIGMINE ER 180 MG TAB?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as PYRIDOSTIGMINE ER 180 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures PYRIDOSTIGMINE ER 180 MG TAB?
PYRIDOSTIGMINE ER 180 MG TAB (NDC 64980022003) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.